Altamira Therapeutics Ltd. (CYTO) has released an update.
At the recent Annual General Meeting, Altamira Therapeutics Ltd. shareholders elected four Board of Directors members and re-elected their auditors for the 2024 financial year. Shareholders also approved the executive compensation, authorized a reduction in share premium account to increase the contributed surplus, and sanctioned an increase in authorized share capital to create additional common shares.
For further insights into CYTO stock, check out TipRanks’ Stock Analysis page.
